EGFR Exon 20 Insertion Mutations — Drug Target

All drugs that target EGFR Exon 20 Insertion Mutations — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

not specified · EGFR tyrosine kinase inhibitor

Marketed (1)

• Pf-06804103 · Pfizer · not specified · Oncology

Phase 3 pipeline (1)

• TAK-788 · Millennium Pharmaceuticals, Inc. · EGFR tyrosine kinase inhibitor · Oncology
  TAK-788 is a selective inhibitor of epidermal growth factor receptor (EGFR) exon 20 insertion mutations.